Evidence-Based Prescribing of Statins: A Developing World Perspective

H. T. Ong

Over the last decade, landmark clinical trials (summarized in Tables 1 and 2) have shown that statin therapy reduces coronary events in patients with or without prior cardiovascular disease [1–12]. More recent studies, summarized in Table 3, show that the larger the statin dosage, the greater the reduction in cardiovascular clinical events [13–17]. A meta-analysis involving 90,056 patients in 14 randomized trials emphasizes that the benefit of statin treatment is not limited to a reduction in coronary disease; treatment also reduces the incidence of strokes, coronary revascularization, and coronary and total mortality [18]. But statins are expensive, and clinicians and policymakers must objectively review the literature so that statin therapy can be appropriately initiated and be cost effective. In developing countries, where a changing lifestyle is increasing the incidence of cardiovascular disease, the need to be cost effective is even more pressing. This paper attempts to derive a fair and evidence-based answer to four practical questions that are especially relevant in less wealthy societies: (1) In whom and when should statin therapy be initiated? (2) What lipid level should physicians aim for? (3) Do different ethnic groups respond differently to statins? and (4) Are statins cost effective?

In Whom and When Should Statins Be Initiated?

Statins should no longer be seen as treatment for hyperlipidemia, but should be viewed as treatment to reduce and prevent clinical cardiovascular events. Thus, those requiring statins are those at high risk of cardiovascular events, regardless of the baseline lipid levels. In assessing the cardiovascular risk of the presenting patient, lipid levels form only one of the many clinical parameters to be taken into consideration [19–21].

A strategy of treatment based on risk will ensure that patients likely to suffer from cardiovascular outcomes will be treated regardless of their initial lipid level, and will avoid unnecessary treatment of the low-risk patient with hyperlipidemia who may not benefit from therapy. The use of lipid level to decide the initiation of treatment must be replaced by the question, “At what cardiovascular risk should statins be started?” Similarly, the individual patient’s risk of possible adverse consequences of treatment (hepatitis, myositis, mood changes) should also dictate how cautious the physician should be in initiating and increasing statin usage.

What Target Lipid Level Should You Aim For?

None of the clinical trials discussed above were designed to answer the question of what lipid level doctors should aim for when prescribing statins to lower a patient’s cardiovascular risk. In contrast, other studies, such as the UK Prospective Diabetes Study Group study and the Hypertension Optimal Treatment study, were specifically designed to determine target levels for reduction of risk factors (such as blood pressure and blood glucose) [22–24].

Based on a post-hoc review of the major statin trials, the Adult Treatment Panel III of the US National Cholesterol Education Program recently concluded: “In high-risk persons, the recommended low-density lipoprotein cholesterol (LDL-C) goal is < 100 mg/dl, but when risk is very high, an LDL-C goal of < 70 mg/dl is a therapeutic option” [25]. This recent advice to seek very low lipid levels indicates the level at which the upper limit of statin dose has been reached. Such an individualized approach to statin therapy reinforces the need for the physician to manage the whole patient clinically, rather than to be excessively distracted by any arbitrarily defined laboratory lipid levels.

The larger the LDL-C reduction, the larger the reduction in vascular disease risk, with a reduction of 1 mmol/l of LDL-C over five years reducing major vascular events by 29% [18]. Accordingly, a higher dose of statin will lead to a greater reduction in cardiovascular events. However, there is an increased incidence of adverse effects with higher doses of statins [13–17]. Thus, the higher-dose statin regime should be reserved for patients at especially high risk of cardiovascular events. The higher the presenting lipid level, the more likely it is that a higher dose of statin can be used.

In any patient, reaching an LDL-C level of 70 mg/dl (1.8 mmol/l) indicates the level at which the statin dosage should not be further increased. The onset of clinical or biochemical adverse effects, or of financial strain upon patients who are having to purchase drugs out of pocket, would similarly suggest that the upper limit of statin dose has been reached. Such an individualized approach to statin therapy reinforces the need for the physician to manage the whole patient clinically, rather than to be excessively distracted by any arbitrarily defined laboratory lipid levels.
Are There Ethnic Differences in Response to Statins?

The landmark statin trials were conducted in the Western world, and ethnic minorities were greatly underrepresented [27,28]. However, the available data suggest that the correlation between elevated cholesterol and coronary disease holds true for all ethnic groups, including Asians and eastern Europeans [29–32]. As people in developing societies attain a more affluent lifestyle and change their dietary habits accordingly, the incidence of dyslipidemia and coronary disease both rise significantly [33,34]. Having said this, the Framingham risk table may not accurately estimate coronary risk amongst Asian patients, and may need to be modified to remain relevant for individuals in developing societies [35–37]. Trial evidence must be adapted to suit local populations.

There are ethnic differences in response to drug treatment. African-Americans, for example, are less affected by agents targeting the renin-angiotensin system than by other drugs for treating heart failure [38,39]. A Japanese study of 51,321 patients found that just 5 mg daily of simvastatin reduced total cholesterol by about 20%, and LDL-C by about 25%; these effects persisted for the six years of the trial [40]. The US Food and Drug Administration notes that serum levels of rosuvastatin amongst Asians is double that of Caucasians, and has advised that rosuvastatin doses should be halved in Asian patients [41].

There is a possibility that smaller and lighter Asians may only require low-dose statin therapy, an idea that would be most welcome in the poorer parts of the world. There are reports that low-dose, alternate-day and even weekly statin therapy can produce efficacious and adequate reduction of lipid levels [42–45]. Yet studies conducted with cerivastatin and simvastatin suggest that pharmacokinetic differences between different ethnic groups do not require clinical dosage modification [46,47]. Ethnic differences in treatment response is an area of research that governmental bodies must look into, given the unwillingness of commercial companies to further pursue this route of enquiry.

Is Statin Therapy Cost-Effective?

Statin therapy of the appropriately high-risk patient has been shown to be cost-effective [48–51]. Prevention of cardiovascular disease is less expensive than the treatment of its clinical consequences. However, while curative medicine benefits the symptomatic and ill patient, preventive medicine treats those at risk, who may or may not develop the disease in future. Thus, practical realities of the local community must be remembered when considering preventive statin therapy.

Developing countries are less affluent than the industrialized world, and funds are needed to combat infectious diseases, to provide for maternal and child health care, and to develop good and clean infrastructure for water and food supplies. The nominal per capita gross domestic product of Malaysia is 12% that of the United States (pp. 388 and 607 of [52]). In Malaysia, treatment for a year with atorvastatin (Lipitor) 80 mg daily costs RM3,139, which is one sixth of the annual Malaysian gross domestic product per capita of RM18,734. Thus, only a small minority can afford this treatment, while the public health system would be rapidly bankrupted if it were to provide high-dose statin for all patients who might benefit from it.

Daily treatment for a year with Lipitor (patented atorvastatin) 10 mg daily costs RM1,606; the same treatment with Zocor (patented simvastatin) 20 mg daily costs RM1,338; treatment with Lescol (patented fluvastatin) 80 mg daily costs RM1,160; treatment with generic simvastatin 20 mg daily costs RM252; and treatment with generic lovastatin daily 40 mg costs RM183. Since the trials clearly show the beneficial effects of simvastatin and lovastatin (which are available off patent), it is difficult to advocate using patented statins in the developing world [1,5–7]. An alternative strategy would be to purchase a high-dose formulation of the expensive patented statin and break the tablet for daily or alternate-day consumption. Breaking Lipitor 80 mg into quarters and taking it on alternate days, producing an effective dose of atorvastatin 10 mg daily, costs RM392 annually. The health care budget even in the developed world is limited, and funds spent extravagantly mean that some other service would have to be shortchanged.

### Table 1. Placebo-Controlled Secondary Prevention Statin Trials

| Variable | Scandinavian Simvastatin Survival Study Group [1] | Cholesterol and Recurrent Events Trial [3] | Long-Term Intervention with Pravastatin in Ischemic Disease Study [4] | Heart Protection Study Collaborative Group [6] | Lescol Intervention Prevention Study [8] |
|----------|-----------------------------------------------|-------------------------------------------|------------------------------------------------|-----------------------------------------------|---------------------------------------|
| Number of patients | 4,444 | 4,159 | 9,014 | 20,536 | 1,677 |
| Duration follow-up (years) | 5.4 | 5 | 6.1 | 5 | 3.9 |
| Statin used | Simvastatin, 5 to 40 mg | Pra, 40 mg | Simvastatin, 40 mg | Fluvastatin, 80 mg |
| Reduction from baseline, total cholesterol | 25% | 20% | 18% | 20% | |
| Reduction from baseline, LDL-C | 35% | 28% | 25% | 29% | 22% |
| Primary end point | Total mortality | Coronary mortality, nonfatal MI | Coronary mortality | Total mortality | Major adverse cardiac events |
| Relative risk with statin treatment (95% confidence interval) | 0.7 (0.58–0.85) | 0.76 (0.64–0.91) | 0.76 (0.65–0.88) | 0.87 (0.81–0.94) | 0.78 (0.69–0.95) |
| Significance (p value) | p = 0.003 | p = 0.003 | p = 0.0001 | p = 0.0003 | p = 0.01 |
| NNT | 25 | 33 | 53 | 56 | 19 |

MI, myocardial infarction; pra, pravastatin.
DOI: 10.1371/journal.pmed.0030050.t001
Discussion

In objectively reviewing the evidence on the statins, it is important not to miss the forest for the trees. While it is true that some trials of statins for reducing cardiovascular disease have had negative results (e.g., the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial [10], the A to Z trial [14], and the trial by the German Diabetes and Dialysis Investigators [53]) nevertheless a meta-analysis involving 90,056 patients did find that statin use was associated with a reduction in cardiovascular end points [18].

In the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial, in which patients aged 55 years or older, with an LDL-C of 120 to 189 mg/dl (or 100 to 129 mg/dl if they had known coronary heart disease) and triglycerides lower than 350 mg/dl, were randomized to pravastatin or usual care, 32% of usual-care participants with and 29% without coronary heart disease started taking lipid-lowering drugs. The fact that so many usual-care participants took lipid-lowering drugs may have reduced the apparent benefit of the statin taken by the treatment group [10]. And although the reduction in primary end point in the A to Z Trial [14] (which compared immediate versus delayed treatment with a statin after an acute coronary syndrome) did not reach statistical significance, the number needed to treat to prevent one primary end point (NNT), was 43. This was similar to the NNT of 45 in the Treating to New Targets Trial (17), which produced a highly significant reduction in primary end point (Table 3). A negative study of statin therapy in 1,255 patients with diabetes on haemodialysis [53] does not reduce the impact of other, larger trials, involving a total of more than 100,000 patients [18,53,54]. The point that these three trials emphasizes is that statin treatment should not be blindly started for all patients with hyperlipidemia but requires a thoughtful assessment of the individual patient.

There must now be a shift in the approach to dyslipidemias. From concentrating solely on lipid levels, the emphasis is now on risk stratification, since treatment will be most effective in patients at high risk of clinical cardiovascular disease. The benefit of statin treatment will thus be greater in secondary prevention, where patients have preexisting atheromatous disease and will be more prone to future adverse events. No decision can be made on the need for statin therapy based solely on lipid levels; all therapeutic decisions must be based on the risk the patient has for future cardiovascular events.

The recent studies suggest that a more aggressive statin treatment strategy will lead to greater reductions in cardiovascular events. However, the incidence of side effects from statin treatment, as well as health care costs, increases with the increased dose used. The most potent of the statins, rosuvastatin, is also the one whose adverse effects have caused alarm—some commentators have even called for its withdrawal [55–57]. Given the need for continuous treatment, the financial burden of patients on high-dose statins, especially in developing countries, may result in reduced adherence to treatment.

Although patients with established cardiovascular disease who have initial low cholesterol levels have been shown to benefit from treatment, the question of which target level of lipids to aim for remains unanswered. The evidence is clear that in conventional doses studied in the trials, daily simvastatin 10 to 80 mg, pravastatin 20 to 40 mg, atorvastatin 10 to 80 mg, lovastatin 20 to 40 mg, and fluvastatin 80 mg will reduce future cardiovascular outcomes. Yet hyperlipidemia is not the only risk factor predisposing to cardiovascular disease, and lowering cholesterol cannot be the sole approach to battle

Table 2. Placebo-Controlled Primary Prevention Statin Trials

| Variable | West of Scotland Coronary Prevention Study [2] | AFCAPS/TexCAPS [5] | Pravastatin in Elderly Individuals at Risk of Vascular Disease [9] | Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial [10] | Anglo-Scandinavian Cardiac Outcomes Trial [11] | Collaborative Atorvastatin Diabetes Study [12] |
|----------|------------------------------------------------|-------------------|---------------------------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|
| Number of patients | 6,595 | 6,605 | 5,804 | 10,355 | 10,305 | 2,838 |
| Duration follow-up (years) | 4.9 | 5.2 | 3.2 | 4.8 | 3.3 | 3.9 |
| Statin used | Pra, 40 mg | Lovastatin, 20 to 40 mg | Pra, 40 mg | Pra, 40 mg | Ator, 10 mg | Ator, 10 mg |
| Reduction from baseline, total cholesterol | 20% | 18% | 10% | 24% | 26% |
| Reduction from baseline, LDL-C | 26% | 25% | 34% | 17% | 35% | 40% |
| Primary end point | Nonfatal MI, coronary mortality | MI, unstable angina, sudden cardiac death | Coronary mortality, nonfatal MI, stroke | Total mortality | Fatal coronary heart disease, nonfatal MI | Acute coronary event, Revascularisation, stroke |
| Relative risk with statin treatment (95% confidence interval) | 0.69 (0.57–0.83) | 0.63 (0.50–0.79) | 0.85 (0.74–0.97) | 0.99 (0.89–1.11) | 0.64 | 0.63 |
| Significance (p value) | p < 0.001 | p < 0.001 | p = 0.014 | p = 0.88 | p = 0.0005 | p = 0.001 |

*Patients not on prior statin saw an LDL-C reduction of 31% and 22% while on atorvastatin and pravastatin 40 mg, respectively. Patients previously on a statin saw further LDL-C reduction of 32% and 0% while on atorvastatin 80 mg and pravastatin 40 mg, respectively.

MI, myocardial infarction; pra, pravastatin; ator, atorvastatin.
Ator, atorvastatin. During the trial mean reduction in LDL-C of 21% was noted with 80 mg atorvastatin and an increase in LDL-C of 3% was noted on continued 10 mg atorvastatin.

### Table 3. Statin Trials Comparing High-Dose with Low-Dose Regimen

| Variable | Pravastatin or Atorvastatin | A to Z Trial [14] | ALLIANCE Study [16] | Treating to New Targets* [17] |
|----------|-----------------------------|------------------|---------------------|-----------------------------|
| Number of patients | 4,162 | 4,497 | 2,442 | 10,001 |
| Duration follow-up (years) | 2 | 2 | 4.5 | 4.9 |
| Statin used | Ator, 80 mg | Pravachol, 40 mg | Early intensive treatment | Ator, 80 mg |
| | | | Delayed, low-dose treatment | Usual care |
| | | | Ator, 10 mg | |
| Reduction from baseline, total cholesterol | 25% | 15% | 24% | 16% |
| Reduction from baseline, LDL-C | 51% (32%)<sup>a</sup> | 22% (0%) | 41% | 27% |
| | | | 34% | 23% |
| | | | 21%<sup>b</sup> | –3% |
| Primary end point | Cardiovascular event | Cardiovascular event | Cardiovascular event | Cardiovascular event |
| Relative risk with high dose treatment (95% CI) | 0.84 (0.74–0.95) | 0.89 (0.76–1.04) | 0.83 (0.71–0.97) | 0.78 (0.69–0.89) |
| Significance (p value) | p = 0.005 | p = 0.14 | p = 0.02 | p < 0.001 |
| NNT | 26 | 43 | 25 | 45 |

<sup>a</sup> All patients on atorvastatin 10 mg daily at baseline.

<sup>b</sup> Patients not on prior statin saw LDL-C reduction of 51% and 22% while on atorvastatin 80 mg and pravastatin 40 mg, respectively. Patients previously on a statin saw further LDL-C reduction of 32% and 9% while on atorvastatin 80 mg and pravastatin 40 mg, respectively.

During the trial median reduction in LDL-C of 21% was noted with 80 mg atorvastatin and an increase in LDL-C of 3% was noted on continued 10 mg atorvastatin.

**Ator, atorvastatin.**

DOI: 10.1371/journal.pmed.0030050.t003

### Conclusion

When deciding whether or not to initiate statin therapy, there should be a shift in emphasis away from the idea of a “normal lipid profile.” Instead, the emphasis should be on the individual patient and the risk factors for cardiovascular disease. The actual threshold for therapy varies between guidelines but the principle remains the same [19–21,35–37]. The higher the risk, assessed from prior atheromatous disease, diabetes, blood pressure, smoking status, age, and sex (besides the lipid levels), the greater the need to treat and to treat aggressively. Indeed, a case can be made for all patients with a prior atheromatous disease to be on a statin, regardless of initial cholesterol level. Patients at low risk of cardiovascular events should not be treated merely because of an abnormal lipid profile, especially since statin treatment is not free from adverse effects. Given the financial costs of statins, it is even more important for physicians with limited resources in developing countries to carefully consider the appropriateness of statin therapy for every patient managed.

### References

1. Scandinavian Simvastatin Survival Study Group (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 344: 1385–1389.
2. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, et al. for the West of Scotland Coronary Prevention Study Group (1990) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333: 1301–1307.
3. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, et al. for the Cholesterol and Recurrent Events Trial Investigators (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. New Engl J Med 335: 1001–1009.
4. Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group (1998) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339: 1549–1557.
5. Downs JR, Clearfield M, Wen S, Whitney E, Shapiro DR, et al. for the AFCAPS/TexCAPS Research Group (1998) Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. JAMA 279: 1615–1622.
6. Heart Protection Study Collaborative Group (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high risk individuals: A randomized placebo controlled trial. Lancet 360: 7–22.
7. Heart Protection Study Collaborative Group (2003) MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomized placebo-controlled trial. Lancet 361: 2005–2016.
8. Serros PW, de Feyer P, Macaya C, Kokott N, Puel J, et al. for the Lescol Intervention Study Group (2002) Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: A randomized controlled trial. JAMA 287: 3215–3222.
9. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley RM, et al., on behalf of the PROSPER study group (2002) Pravastatin in elderly individuals at risk of cardiovascular disease (PROSPER): A randomised controlled trial. Lancet 360: 1625–1630.
10. The ALLHAT Officer and Coordinators for the ALLHAT Cooperative Research Group (2002) Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LTT). JAMA 288: 3098–3107.
11. Sever PS, Dahlof B, Poulter NR, Wedel H, Beavers G, et al. (2003) Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): A multicentre randomized controlled trial. Lancet 361: 1169–1179.
12. Colquhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, et al. on behalf of the CARDS investigators (2004) Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomized placebo-controlled trial. Lancet 364: 685–696.
13. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, et al., for the Pravastatin or Atorvastatin Evaluation and Infection Therapy—Thrombolysis in Myocardial Infarction 22 Investigators (2004) Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350: 1495–1505.
14. De Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, et al. for the A to Z investigators (2004) Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: Phase Z of the A to Z trial. JAMA 292: 1307–1316.
15. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Gaziano P, et al. for the REVERSAL Investigators (2004) Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherothrombosis: A randomized controlled trial. JAMA 291: 1071–1080.

**This health problem. Treatment of other risk factors, such as diabetes and hypertension, as well as lifestyle changes that include increasing physical activity, cessation of smoking, and dietary modification, all have an important role to play in the prevention of cardiovascular disease [58]. No medicine is free of adverse effects, and the risk-benefit ratio of treatment in each patient must be carefully considered before initiating statin therapy.**
16. Koren MJ, Hunninghake DB, on behalf of the ALLIANCE Investigators (2004) Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid lowering disease management clinics. The ALLIANCE Study. J Am Coll Cardiol 44: 1772–1779.

17. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, et al. for the Treating to New Targets (TNT) Investigators (2005) Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 353: 1425–1435.

18. Cholesterol Treatment Trials’ (CTT) Collaborators (2005) Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90056 participants in 14 randomised trials of statins. Lancet 366: 1267–1278.

19. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 285: 2486–2497.

20. Conroy RM, Pyorala K, Bhatnagar D, France D, Menotti A, et al. for the Coordinating Committee of the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 101: 218–231.

21. Durrington PN, Prais H, Bhatnagar D, France M, Crowley V, et al. (1999) Indications for cholesterol-lowering medication: Comparison of risk-assessment methods. Lancet 353: 278–281.

22. UK Prospective Diabetes Study Group (1998) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J 317: 705–712.

23. UK Prospective Diabetes Study Group (1998) Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 53). Lancet 352: 837–854.

24. Hanson RL, Cefalu WT, Sosenko J, Abe K, Knowler WC (1995) Serum lipoprotein mass and cardiovascular risk: Findings of the Diabetes Control and Complications Trial. J Clin Endocrinol Metab 80: 1907–1912.

25. Grundy SM, Cleeman JI, Merz CN, Brewer HB, Clark LT, et al. for the Coordinating Committee of the National Cholesterol Education Program (2004) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110: 227–239.

26. O’Keefe JH Jr, Cordain L, Harris WH, Moe RM, Vogel R (2004) Optimal low-density lipoprotein is 50 to 70 mg/dL. Lower is better and physiologically normal. J Am Coll Cardiol 43: 2142–2146.

27. Barnett AH (2005) Deslipidemia in ethnic populations: Special considerations. J Renin Angiotensin Aldosterone Syst 12: 118–122.

28. Bartlett C, Davey P, Dieppe P, Doyal L, Ebrahim S, et al. (2003) Women, older persons and ethnic minorities: Factors associated with their inclusion in randomized trials of statins 1990 to 2001. Heart 89: 327–328.

29. Asia Pacific Cohort Studies Collaboration (2005) Cholesterol, coronary heart disease, and stroke in the Asia Pacific region. Int J Epidemiol 34: 559–572.

30. Simons LA (1986) Interrelations of lipids and lipoproteins with coronary artery disease mortality in 19 countries. Am J Cardiol 57: 5G–10G.

31. Verschuren WM, Jacobs DR, Bloemsma M, Kromhout D, Menotti A, et al. (1995) Serum total cholesterol and long-term coronary heart disease mortality in different cultures: Twenty-five-year follow-up of the seven countries study. JAMA 274: 131–136.

32. Cai J, Pajak A, Li Y, Shestov D, Davis CE, et al. (2004) Total cholesterol and mortality in China, Poland, Russia, and the US. Ann Epidemiol 14: 399–408.

33. McLaughlin JB, Middaugh JP, Utermohl CT, Asay ED, Fenaughty AM, et al. (2004) Changes in serum lipids, apolipoproteins, and lipoprotein(a) and coronary heart disease mortality among Alaska Natives, 1979–2002. JAMA 291: 2545–2546.

34. Critchley J, Lin J, Zhao D, Wei W, Capewell S (2004) Exploring the increment in coronary heart disease mortality in Beijing between 1984 and 1999. Circulation 110: 1256–1244.

35. Liu J, Hong Y, D’Agostino RB Sr, Wu Z, Wang W, et al. (2004) Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi-Provincial Cohort Study. JAMA 291: 2591–2599.

36. Aarabi M, Jackson PR (2005) Predicting coronary risk in UK South Asians: An adjustment method for Framingham-based tools. Eur J Cardiovasc Prev Rehabil 12: 46–51.

37. D’Agostino RB Sr, Grundy S, Sullivan LM, Wilson P for the CHD Risk Prediction Group (2001) Validation of the Framingham coronary heart disease prediction scores: Results of a multiple-center validations investigation. JAMA 286: 186–187.

38. Taylor JS, Ellis GR (2002) Racial differences in responses to drug treatment: Implications for pharma genetic research and patient risk. Am J Cardiovasc Drugs 2: 389–399.

39. Cavallari LH, Fashingbauer LA, Beitelshies AL, Groo VL, Southworth MR, et al. (2004) Racial differences in patients’ potassium concentrations during spironolactone therapy for heart failure. Pharmacotherapy 24: 750–757.

40. Mangin EF, Robles GI, Jones WN, Ford MA, Sperling RL, et al. (2005) Comparing hyperlipidemia control with daily versus twice-weekly simvastatin. Ann Pharmacother 39: 1789–1793.

41. Cuddy J, O’Sullivan N, Kaswan K, Ahr G (1998) Inter-ethnic comparisons of the pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin. Br J Clin Pharmacol 45: 538–550.

42. Tan CE, Loh LM, Tan ES (2005) Do Singapore patients require lower dose of statins? The SGH Lipid Clinic experience. Singapore Med J 44: 635–636.

43. Goldsmith L, Weinstein MC, Goldman PA, Wolf PA for the HMG-CoA reductase inhibitor treatment with minimum side effects in 51,321 participants: The CHD outcomes in managed-care patients with type 2 diabetes mellitus undergoing haemodialysis. N Engl J Med 353: 238–258.

44. Prosser LA, Sinnet AA, Goldman PA, Williams LW, Hunink MG, et al. (2000) Cost effectiveness of cholesterol-lowering therapies according to selected patient characteristics. Ann Intern Med 132: 769–779.

45. van Hout BA, Simoons ML (2001) Cost-effectiveness of HMG coenzyme reductase inhibitors: Who to treat? Eur Heart J 22: 751–761.

46. Financial Times (2005) Financial times world desk reference. 5th Edition. London: Dorling Kindersley Limited. 736 p.

47. Wanner C, Kranke V, Marz W, Oslcheski M, Mann JF, et al. for the German Diabetes and Dialysis Investigators. (2005) Atorvastatin in patients with type 2 diabetes mellitus undergoing haemodialysis. N Engl J Med 353: 1789–1793.

48. Ong HT (2005) The statin studies: From targeting hypercholesterolemia to targeting the high-risk patient. Q J Med 98: 599–614.

49. Wolfe SM (2004) Dangers of rosuvastatin identified before and after FDA approval. Lancet 363: 2188–2190.

50. Florentinus SR, Heerdink ER, Klungel OH, de Boer A (2004) Should rosuvastatin be withdrawn from the market? Lancet 364: 1577.

51. Kastelein JP (2004) Should rosuvastatin be withdrawn from the market? Lancet 364: 1577–1578.

52. Davius ML, Liu K (2004) Today’s agenda. We must focus on achieving favorable levels of all risk factors simultaneously. Arch Intern Med 164: 2086–2087.